By GLP-1 StudioGLP1Coach
← All tools

Free tool · GLP-1 comparison

Every GLP-1, compared simply.

Pick a medication, from Wegovy and Zepbound through to the newer ones still in development, and see what it is approved for, how it is taken, how it works, and what the trials found. You can also put two or more side by side when you are trying to understand the differences.

Available now

Coming

No longer made

Highlight up to 4 to compare them in a table.

Every trial stage, compared

Each column is a different stage of testing, and the numbers are not interchangeable. Phase 1 trials are small and short, phase 2 trials find the dose, and phase 3 trials are the large, long ones an approval rests on. Read across a row to see how one medication held up as testing grew; compare down a column only within the same stage.

Phase 1Small, weeks long, mainly a safety checkPhase 2A few hundred people, finding the dosePhase 3Thousands of people, a year or more, what approval rests on
WegovyAvailable by prescriptionNo published result13.8% lost, vs 2.3% on placeboPhase 2 dose-finding · 52 weeks · Adults with obesity, no diabetesSource14.9% lost, vs 2.4% on placeboSTEP 1 · 68 weeks · Adults with obesity or overweight, no diabetesSource
Wegovy HDAvailable by prescriptionNo published resultNo published result18.7% lost, vs 15.6% on 2.4 mg and 3.9% on placeboSTEP UP · 72 weeks · Adults with obesity, no diabetesSource
ZepboundAvailable by prescriptionAbout 5 kg (11 lb) more lost than on placebo, measured in kilograms onlyFirst-in-human · 4 weeks · Healthy adultsSource11.3 kg (25 lb) lost, vs 0.4 kg on placeboPhase 2 · 26 weeks · Adults with type 2 diabetesSource20.9% lost, vs 3.1% on placeboSURMOUNT-1 · 72 weeks · Adults with obesity or overweight, no diabetesSource
SaxendaAvailable by prescriptionNo published result7.2 kg (16 lb) lost, vs 2.8 kg on placeboPhase 2 · 20 weeks · Adults with obesity, no diabetesSource8.4 kg lost (about 8%), vs 2.8 kg (about 3%) on placeboSCALE Obesity and Prediabetes · 56 weeks · Adults with obesity or overweight, no diabetesSource
FoundayoAvailable by prescriptionUp to 5.4 kg (12 lb) lost, vs 2.4 kg on placeboPhase 1a · 4 weeks · Healthy adultsSource9.4% to 14.7% lost, vs 2.3% on placeboPhase 2 · 36 weeks · Adults with obesity or overweight, no diabetesSource11.2% lost, vs 2.1% on placeboATTAIN-1 · 72 weeks · Adults with obesity or overweight, no diabetesSource
CagriSemaComing, but not available yet17.1% lost, vs 9.8% on semaglutide alone (no true placebo)Phase 1b · 20 weeks · Adults with overweight or obesity, no diabetesSource15.6% lost, vs 5.1% on semaglutide alone (no placebo arm, 92 people)Phase 2 · 32 weeks · Adults with type 2 diabetesSource20.4% lost, vs 3.0% on placeboREDEFINE 1 · 68 weeks · Adults with obesity or overweight, no diabetesSource
RetatrutideComing, but not available yetUp to 9.0 kg (20 lb) more lost than on placebo, measured in kilograms onlyPhase 1b · 12 weeks · Adults with type 2 diabetesSource24.2% lost, vs 2.1% on placeboPhase 2 · 48 weeks · Adults with obesity or overweight, no diabetesSource25.0% lost, vs 3.9% on placeboTRIUMPH-1 · 80 weeks · Adults with obesity or overweight, no diabetesSource
EloralintideComing, but not available yet2.6% to 11.3% lost across dosesPhase 1 multiple dose · 12 weeks · Adults with obesity or overweightSource20% lost, vs 0.4% on placebo, if everyone stayed on itPhase 2 · 48 weeks · Adults with obesity or overweight, no diabetesSourceRecruiting. No results yetENLIGHTEN-1 · 64 weeks · Adults with obesity or overweight, no diabetesSource
Eloralintide + tirzepatideComing, but not available yet29% lost, vs 17.8% on tirzepatide 15 mg alonePhase 1b · 31 weeks · Adults with obesity or overweight, no diabetesSource23.3% lost, vs 14.8% on tirzepatide 15 mg alonePhase 2 · 48 weeks · Adults with obesity and type 2 diabetesSourceNo published result
MariTideComing, but not available yet14.5% lost, vs a 1.5% gain on placebo (8 people per group)Phase 1 · 12 weeks · Adults with obesity, no diabetesSource12.3% to 16.2% lost, vs 2.5% on placeboPhase 2 · 52 weeks · Adults with obesity or overweight, no diabetesSourceUnderway. No results yetMARITIME-1 · 72 weeks · Adults with obesity or overweight, no diabetesSource
AmycretinComing, but not available yet24.3% lost, vs 1.1% on placebo, if everyone stayed on it (125 people, one site)Phase 1b/2a (the injection) · 36 weeks · Adults with overweight or obesity, no diabetesSource14.6% lost, vs 2.1% on placebo, if everyone stayed on itPhase 2 in diabetes (the injection) · 36 weeks · Adults with type 2 diabetesSourceNo published result
SurvodutideComing, but not available yetNo published result14.9% lost, vs 2.8% on placeboPhase 2 · 46 weeks · Adults with obesity or overweight, no diabetesSource13.0% lost, vs 5.4% on placeboSYNCHRONIZE-1 · 76 weeks · Adults with obesity or overweight, no diabetesSource

This is education, not a recommendation

Which of these fits you, if any, depends on your health history, your insurance, and your prescriber's judgment. Trial percentages are averages from different trials, at different stages, with different lengths and populations, so treat them as a rough map, not a ranking. Unless a result says "if everyone stayed on it", it counts everyone who started the drug, including people who stopped, which is how the journals report it; company headlines often use the stayed-on figure, which runs 2 to 3 points higher. Bring this page to your appointment if it helps the conversation; do not use it in place of one.

Sources

50 references
  1. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. Current label at DailyMed and the FDA label for Wegovy tablets. Indications including cardiovascular risk reduction and MASH, and the oral tablet approval.
  2. Zepbound (tirzepatide) Prescribing Information. Eli Lilly. FDA label. The weight-management and obstructive sleep apnea indications.
  3. Ozempic (semaglutide) injection Prescribing Information. Novo Nordisk. Current label. The type 2 diabetes, cardiovascular, and chronic kidney disease indications.
  4. Rybelsus and Ozempic (oral semaglutide) tablets Prescribing Information. Novo Nordisk. Current label at DailyMed. The one label now covering both names, and the source for the Ozempic tablet dosing and for the two products not being substitutable milligram for milligram.
  5. Foundayo (orforglipron) approval. Eli Lilly, 1 April 2026. Company announcement. The approval date, the weight-management indication, and the absence of food, water and timing restrictions.
  6. Wegovy HD (semaglutide 7.2 mg) approval. Novo Nordisk, 19 March 2026. Company announcement. The approval date and the step-up indication for people already on 2.4 mg.
  7. Mounjaro cardiovascular approval, 28 August 2026. Healio report. The new heart attack, stroke and cardiovascular death indication from SURPASS-CVOT.
  8. CagriSema FDA submission. Novo Nordisk, 18 December 2025. Company announcement, and the expected decision timing in the 21 September 2026 update.
  9. Retatrutide filing plans. Eli Lilly, 23 July 2026. Company announcement. The plan to submit to the FDA in the first quarter of 2027.
  10. ASHP Drug Shortages Database: Exenatide. ashp.org. Documentation of the Byetta and Bydureon discontinuations.

Trial results, every stage

  1. Wegovy, phase 2, Phase 2 dose-finding. O'Neil PM, et al. Lancet. 2018;392:637-649. doi:10.1016/S0140-6736(18)31773-2
  2. Wegovy, phase 3, STEP 1. Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  3. Wegovy, phase 3, OASIS 4 (the pill). Wharton S, et al. N Engl J Med. 2025;393:1077-1087. doi:10.1056/NEJMoa2500969
  4. Wegovy HD, phase 3, STEP UP. Wharton S, et al. Lancet Diabetes Endocrinol. 2025;13:949-963. doi:10.1016/S2213-8587(25)00226-8
  5. Wegovy HD, phase 3, STEP UP T2D. Lingvay I, et al. Lancet Diabetes Endocrinol. 2025;13:935-948. doi:10.1016/S2213-8587(25)00225-6
  6. Zepbound, phase 1, First-in-human. Coskun T, et al. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  7. Zepbound, phase 2, Phase 2. Frias JP, et al. Lancet. 2018;392:2180-2193. doi:10.1016/S0140-6736(18)32260-8
  8. Zepbound, phase 3, SURMOUNT-1. Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
  9. Zepbound, phase 3, SURMOUNT-5 (vs Wegovy). Aronne LJ, et al. N Engl J Med. 2025;393:26-36. doi:10.1056/NEJMoa2416394
  10. Saxenda, phase 2, Phase 2. Astrup A, et al. Lancet. 2009;374:1606-1616. doi:10.1016/S0140-6736(09)61375-1
  11. Saxenda, phase 3, SCALE Obesity and Prediabetes. Pi-Sunyer X, et al. N Engl J Med. 2015;373:11-22. doi:10.1056/NEJMoa1411892
  12. Foundayo, phase 1, Phase 1a. Pratt E, et al. Diabetes Obes Metab. 2023;25:2634-2641. doi:10.1111/dom.15184
  13. Foundayo, phase 2, Phase 2. Wharton S, et al. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392
  14. Foundayo, phase 3, ATTAIN-1. Wharton S, et al. N Engl J Med. 2025;393:1796-1806. doi:10.1056/NEJMoa2511774
  15. Foundayo, phase 3, ATTAIN-2. Horn DB, et al. Lancet. 2025;406:2927-2944. doi:10.1016/S0140-6736(25)02165-8
  16. CagriSema, phase 1, Phase 1b. Enebo LB, et al. Lancet. 2021;397:1736-1748. doi:10.1016/S0140-6736(21)00845-X
  17. CagriSema, phase 2, Phase 2. Frias JP, et al. Lancet. 2023;402:720-730. doi:10.1016/S0140-6736(23)01163-7
  18. CagriSema, phase 3, REDEFINE 1. Garvey WT, et al. N Engl J Med. 2025;393:635-647. doi:10.1056/NEJMoa2502081
  19. CagriSema, phase 3, REDEFINE 2. Davies MJ, et al. N Engl J Med. 2025;393:648-659. doi:10.1056/NEJMoa2502082
  20. CagriSema, phase 3, REDEFINE 4 (vs Zepbound). Novo Nordisk company announcement, 23 February 2026. www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm
  21. Retatrutide, phase 1, Phase 1b. Urva S, et al. Lancet. 2022;400:1869-1881. doi:10.1016/S0140-6736(22)02033-5
  22. Retatrutide, phase 2, Phase 2. Jastreboff AM, et al. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972
  23. Retatrutide, phase 2, Phase 2 in diabetes. Rosenstock J, et al. Lancet. 2023;402:529-544. doi:10.1016/S0140-6736(23)01053-X
  24. Retatrutide, phase 3, TRIUMPH-1. Jastreboff AM, et al. N Engl J Med. Published online 29 September 2026. doi:10.1056/NEJMoa2604169
  25. Retatrutide, phase 3, TRIUMPH-2. Bellido V, et al. Lancet. 2026;408:1455-1472. doi:10.1016/S0140-6736(26)01861-1
  26. Retatrutide, phase 3, TRIUMPH-4. Eli Lilly company announcement, 11 December 2025. www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
  27. Eloralintide, phase 1, Phase 1 multiple dose. Bhattachar S, et al. Diabetes Obes Metab. 2026;28:2651-2660. doi:10.1111/dom.70439
  28. Eloralintide, phase 2, Phase 2. Billings LK, et al. Lancet. 2025;406:2631-2643. doi:10.1016/S0140-6736(25)02155-5
  29. Eloralintide, phase 3, ENLIGHTEN-1. ClinicalTrials.gov NCT07321886. clinicaltrials.gov/study/NCT07321886
  30. Eloralintide + tirzepatide, phase 1, Phase 1b. Eli Lilly, reported September 30, 2026 (On The Pen). onthepen.com/news/lillys-tirzepatide-eloralintide-combo
  31. Eloralintide + tirzepatide, phase 2, Phase 2. Presented at EASD 2026, Milan, reported September 30, 2026 (CNBC). www.cnbc.com/2026/09/30/eli-lilly-obesity-drug-amylin-tirzepatide-weight-loss-trial.html
  32. MariTide, phase 1, Phase 1. Véniant MM, et al. Nat Metab. 2024;6:290-303. doi:10.1038/s42255-023-00966-w
  33. MariTide, phase 2, Phase 2. Jastreboff AM, et al. N Engl J Med. 2025;393:843-857. doi:10.1056/NEJMoa2504214
  34. MariTide, phase 3, MARITIME-1. ClinicalTrials.gov NCT06858839. clinicaltrials.gov/study/NCT06858839
  35. Amycretin, phase 1, Phase 1 (the pill). Gasiorek A, et al. Lancet. 2025;406:135-148. doi:10.1016/S0140-6736(25)01176-6
  36. Amycretin, phase 1, Phase 1b/2a (the injection). Dahl K, et al. Lancet. 2025;406:149-162. doi:10.1016/S0140-6736(25)01185-7
  37. Amycretin, phase 2, Phase 2 in diabetes (the injection). Mora P, et al. Lancet. 2026;408:621-635. doi:10.1016/S0140-6736(26)01248-1
  38. Survodutide, phase 2, Phase 2. le Roux CW, et al. Lancet Diabetes Endocrinol. 2024;12:162-173. doi:10.1016/S2213-8587(23)00356-X
  39. Survodutide, phase 3, SYNCHRONIZE-1. le Roux CW, et al. N Engl J Med. 2026;395:776-787. doi:10.1056/NEJMoa2600751
  40. Survodutide, phase 3, SYNCHRONIZE-2. Wharton S, et al. N Engl J Med. Published online 1 October 2026. doi:10.1056/NEJMoa2607219

Coaching

Would it help to talk this through with me?

A guide can lay out the options. Coaching helps you get ready for the conversation with your prescriber, the person who actually weighs them for you.

Work with me →